Clinical Trial

HIPEC Surgery and Hemodynamics

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 13, 2025 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) involves the intraoperative administration of heated chemotherapeutic agents into the abdominal cavity following cytoreductive surgery (CRS). The increasing use of CRS combined with HIPEC has introduced certain procedural and physiological considerations that distinguish it from other surgical interventions, posing unique challenges for researchers and clinicians alike. Despite advancements in surgical and anesthetic techniques, this combined approach is frequently associated with significant hemodynamic instability, coagulation abnormalities, respiratory complications, and nutritional imbalances. The study aims to contribute to the existing body of knowledge by examining the physiological alterations induced by HIPEC, thereby offering practical insights and guidance for investigators involved in the management and study of this complex therapeutic modality.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-09.
Trial Details
NCT Number NCT06922227
Lead Sponsor Miray Gözde Özdemir
Conditions Hemodynamics, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Enrollment 15 participants
Start Date 2025-04-01
Primary Completion 2025-07-01 (estimated)
Study Completion 2025-07-15 (estimated)
Updated on ClinicalTrials.gov 2025-04-13